|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.00 JPY | +3.12% |
|
+11.86% | -15.38% |
| 07-02 | Ribomic Enrolls First Patient in Phase III Trials of Umedaptanib Pegol for Achondroplasia Treatment | MT |
| 05-14 | Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2026 | CI |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bearish | Bearish |
| Resistance | 66 | 81 | 85 |
| Spread/Res. | 0.00% | -18.52% | -22.35% |
| Spread/Supp. | +13.79% | +13.79% | +11.86% |
| Support | 58 | 58 | 59 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- 4591 Stock
- Charts Ribomic Inc.
Select your edition
All financial news and data tailored to specific country editions
